Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10681854 | 0.85 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL7281021 | 0.85 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL20641486 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL17275347 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL5288444 | 0.80 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL15390938 | 0.80 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL18248063 | 0.80 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL18248060 | 0.80 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL29057555 | 0.79 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1NOS2 | |
| SCHEMBL29032593 | 0.79 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | TRUSTEES OF TUFTS COLLEGE | 2009-12-31 | — | — | US | claimed |
| EP-1993582-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | Trustees Of Tufts College (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007084527-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-26 | — | — | WO | claimed |
| EP-4071477-B1 | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | QIAGEN SCIENCES LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240384267-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS | THE BROAD INSTITUTE, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240361314-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | QIAGEN SCIENCES LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240294586-A1 | TENASCIN-C AUTOANTIGENIC EPITOPES IN RHEUMATOID ARTHRITIS | BENAROYA RES INSTITUTE AT VIRGINIA MASON (US) | 2024-09-05 | — | — | US | disclosed |
| US-12066436-B2 | Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment | QIAGEN SCIENCES LLC (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240027450-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY | QIAGEN SCIENCES LLC | 2024-01-25 | — | — | US | disclosed |
| EP-4256334-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY | Qiagen Sciences LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023069816-A2 | COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS | THE BROAD INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2008005531-A2 | C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080008701-A1 | C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007084527-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2007-05-17 | — | — | US | disclosed |
| US-7132559-B2 | Non-racemic hexafluoroleucine, and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040138493-A1 | Non-racemic hexafluoreleucine, and methods of making and using it | TRUSTEES OF TUFTS COLLEGE | 2004-07-15 | — | — | US | disclosed |
| WO-2002068592-A2 | NON-RACEMIC HEXAFLUORELEUCINE, AND METHODS OF MAKING AND USING IT | TRUSTEES OF TUFTS COLLEGE (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | DNPEP, NPEPPS, ANPEP | SLC7A5 618/4885SLC1A3 385/4885SLC1A2 647/4885 |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | CRYZ, FABP5, FAU | SLC7A5 1167/4885SLC1A3 2513/4885SLC1A2 2705/4885 |
| US-20040138493-A1 | Non-racemic hexafluoreleucine, and methods of making and using it | NPFFR1, FNTB, CRYZ | SLC7A5 1102/4885SLC1A3 2419/4885SLC1A2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.